Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.53 |
| ▸ | AAK1 | Q2M2I8 | 12/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP21A2 | P08686 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12763018 | 1.00 | ROCK2 (0.53) | ROCK2AAK1ROCK1CYP17A1CYP21A2 | |
| SCHEMBL12763518 | 0.86 | ROCK2 (0.54) | ROCK2AAK1ROCK1CYP17A1CYP11B1 | |
| SCHEMBL1519155 | 0.86 | ROCK2 (0.54) | ROCK2AAK1ROCK1CYP17A1CYP11B1 | |
| SCHEMBL1519150 | 0.86 | ROCK2 (0.54) | ROCK2AAK1ROCK1CYP17A1CYP11B1 | |
| SCHEMBL12836762 | 0.86 | ROCK2 (0.70) | ROCK2AAK1ROCK1 | |
| SCHEMBL1519250 | 0.86 | ROCK2 (0.70) | ROCK2AAK1ROCK1 | |
| SCHEMBL1519324 | 0.84 | AAK1 (0.55) | ROCK2AAK1ROCK1 | |
| SCHEMBL12836750 | 0.84 | AAK1 (0.55) | ROCK2AAK1ROCK1 | |
| SCHEMBL12763520 | 0.84 | ROCK2 (0.55) | ROCK2AAK1ROCK1 | |
| SCHEMBL1519244 | 0.84 | ROCK2 (0.55) | ROCK2AAK1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110052562-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052562-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | ROCK1, ROCK2, ARHGDIB | ROCK2 2/4885AAK1 532/4885ROCK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.